MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
11.50
-1.23
-9.66%
After Hours: 11.45 -0.05 -0.43% 19:52 09/29 EDT
OPEN
12.83
PREV CLOSE
12.73
HIGH
13.09
LOW
10.84
VOLUME
856.27K
TURNOVER
--
52 WEEK HIGH
17.79
52 WEEK LOW
8.60
MARKET CAP
432.64M
P/E (TTM)
-6.6198
1D
5D
1M
3M
1Y
5Y
1D
Analyst Maintains Buy Rating on Contineum (CTNM) with Unchanged $23 Price Target, Citing Positive Readthrough from Bristol Myers Squibb’s ALOFT-IPF Trial
TipRanks · 12h ago
Contineum Therapeutics Inc trading resumes
TipRanks · 12h ago
Contineum Therapeutics Inc trading halted, volatility trading pause
TipRanks · 12h ago
Weekly Report: what happened at CTNM last week (0921-0925)?
Weekly Report · 1d ago
Contineum price target lowered to $17 from $18 at Morgan Stanley
TipRanks · 2d ago
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading
TipRanks · 2d ago
Contineum participates in a conference call with William Blair
TipRanks · 5d ago
Contineum resumed at Early-Stage Biotech at Goldman Sachs
TipRanks · 5d ago
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.